EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis

Markus Peck-Radosavljevic, Akhmed Abdelgafur, Alessandro Granito, Antonio Gasbarrini, Yuk Ting Ma, Edward Mena, José Luis Lledó-Navarro, José Presa, Arndt Weinmann, Miriam T Levy, Adriano Pellicelli, Dirk-Thomas Waldschmidt und 6 weitere

Liver Cancer · 24.04.2026 · 1-11

DOI: 10.1159/000552115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 24.04.2026. Verfasst von Markus Peck-Radosavljevic und 17 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Internal Medicine and Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Nephrology, Klinikum Klagenfurt am Wörthersee, Kl…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The phase 3 REFLECT trial demonstrated the efficacy and safety of lenvatinib versus sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma (uHCC). We report results from STELLAR, a non-interventional post-marketing study. The primary objectives were to characterize hepatotoxicity and overall safety of lenvatinib in patients from Western regions with uHCC.

Methods

STELLAR was a prospective, open-label, observational, phase 4 study of patients treated with lenvatinib (n = 193). A cohort of sorafenib-treated patients (n = 123) was included as an internal reference group. The treating physician made the decision to treat patients with lenvatinib or sorafenib before enrollment. Study drugs were administered according to the Summary of Product Characteristics guidelines. Safety and efficacy evaluations were performed according to standard clinical practice at each site. The primary endpoint was safety. Secondary endpoints included treatment exposure and overall survival.

Results

The median duration of treatment with lenvatinib or sorafenib was 6.5 months (range, 0.2–33.1 months) and 4.4 months (range, 0.5–30.7 months), respectively. Hepatotoxicity treatment-emergent adverse events (TEAEs) were observed in 26.9% of lenvatinib-treated patients and 33.3% of sorafenib-treated patients. The most frequently reported hepatotoxicity TEAEs were hepatic encephalopathy (7.8%; lenvatinib cohort) and ascites (11.4%; sorafenib cohort), respectively. Overall, 85.0% of lenvatinib-treated patients and 84.6% of sorafenib-treated patients experienced ≥1 TEAE. Median overall survival (95% CI) was 16.9 months (14.1–not estimable) in lenvatinib-treated patients.

Conclusion

Our findings support the established safety and efficacy of lenvatinib in first-line patients with uHCC.

Schlagwörter

Stichwörter der Autor:innen

Hepatocellular carcinomaLenvatinibPhase 4Sorafenib

Autor:innen und Institutionen

  • Departments of Internal Medicine and Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Nephrology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
  • Departments of Oncology, Nizhny Novgorod Regional Clinical Oncological Dispensary, Nizhny Novgorod, Russia.
  • Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy.
  • Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
  • The Cancer Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.
  • Pasadena Liver Center, California Liver Research Institute, Pasadena, CA, USA.

Zitieren

APA

Peck-Radosavljevic, M., Abdelgafur, A., Granito, A., Gasbarrini, A., Ma, Y. T., Mena, E., Lledó-Navarro, J. L., Presa, J., Weinmann, A., Levy, M. T., Pellicelli, A., Waldschmidt, D. T., Sørensen, H. T., Goyal, L., Ren, M., Saal, H., Okpara, C. E., & Meyer, T. (2026). An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis. Liver Cancer, 1-11. https://doi.org/10.1159/000552115

Vancouver

Peck-Radosavljevic M, Abdelgafur A, Granito A, Gasbarrini A, Ma YT, Mena E, et al. An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis. Liver Cancer. 2026:1-11. doi:10.1159/000552115

BibTeX
@article{PeckRadosavljevic2026,
  author = {Peck-Radosavljevic, Markus and Abdelgafur, Akhmed and Granito, Alessandro and Gasbarrini, Antonio and Ma, Yuk Ting and Mena, Edward and Lledó-Navarro, José Luis and Presa, José and Weinmann, Arndt and Levy, Miriam T and Pellicelli, Adriano and Waldschmidt, Dirk-Thomas and Sørensen, Henrik Toft and Goyal, Lipika and Ren, Min and Saal, Hakim and Okpara, Chinyere E and Meyer, Tim},
  title = {An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis},
  journal = {Liver Cancer},
  year = {2026},
  pages = {1--11},
  doi = {10.1159/000552115}
}
Kostenlos starten →